Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether using FOLFIRINOX chemotherapy and
Stereotactic Body Radiation Therapy (SBRT) prior to surgery in patients with pancreatic
cancer is safe and well tolerated. This study will obtain preliminary data on the response of
the cancer to this therapy by Magnetic Resonance Imaging (MRI) and by studying the cancer
after it is resected surgically.
In addition, the investigators will perform biochemical studies on the tumor tissue obtained
from your tissue biopsy as well as from the tumor removed by the surgeon in order to measure
the effect of treatment with FOLFIRINOX and SBRT on several proteins that may be important in
the behavior of pancreatic cancer cells.
The data obtained from this trial will be extremely valuable to help improve the approach to
treating pancreatic cancer in the future. If you do not undergo surgery after completion of
FOLFIRINOX + SBRT, the investigators will request a second biopsy of the tumor under computer
tomography (CT) -guidance in order to measure the effect of treatment on your tumor.